Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of MEDI8662 (Q/LAIV-BFS) vs FluMist in Adults
NCT00952705Phase 3Completed
- Sponsor
- MedImmune
- Start
- Aug 2009
- Primary completion
- Jan 2010
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of MEDI8662 in influenza (3 arms), sponsored by MedImmune. Primary endpoint: Post Dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers. Started Aug 2009; status: completed.
02
Drugs
MEDI8662
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00952705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00952705.